Shanghai Fosun Pharmaceutical (02196): Application for registration of oxazepam tablets received approval from the National Medical Products Administration

20/01/2025

GMT Eight

Shanghai Fosun Pharmaceutical (02196) announced that the application for the listing registration of oxazepam tablets (hereinafter referred to as "the drug") of its controlling subsidiary, Hunan Dongting Pharmaceutical Co., Ltd., was recently approved by the National Medical Products Administration.

Guangzhou Echom Sci.&Tech. Co,. (002420.SZ) has announced a expected profit, with an estimated net profit for the year 2024 of 80 million to 120 million yuan.

China Railway Signal & Communication Corporation (688009.SH) won contracts for approximately 4.567 billion yuan in important rail transit projects from November to December.

Contact: contact@gmteight.com

Shanghai Fosun Pharmaceutical (02196): Application for registration of oxazepam tablets received approval from the National Medical Products Administration

RECOMMEND

Shenzhen Kexin Communication Technologies (300565.SZ) issues a profit warning, expecting a net loss of 195 million to 211 million yuan for the fiscal year 2024.

Jiangxi GETO New Materials Corporation (300986.SZ) forecasts a profit increase, with an estimated net profit of 65 million to 95 million yuan in 2024, turning losses into profits.

Chongqing Polycomp International Corporation (301526.SZ) forecasts a net loss of 280 million to 372 million yuan in 2024.